Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Japanese participants with chronic plaque psoriasis who completed the blinded, placebo-controlled Study M04-688 (NCT00338754; 24-week duration) enrolled in the extension study, M04-702, an open-label study until adalimumab received approval for treatment of psoriasis in Japan.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Adalimumab 40 mg Every Other Week	Participants who had received adalimumab 40 mg eow during Study M04-688 (NCT00338754) or who had received placebo during Study M04-688 (NCT00338754) and were re-randomized to receive adalimumab 40 mg eow during this study.
Adalimumab 80 mg Every Other Week	Participants who had received adalimumab 80 mg eow during Study M04-688 (NCT00338754) or who had received placebo during Study M04-688 (NCT00338754) and were re-randomized to receive adalimumab 80 mg eow during this study. All participants had to reduce their dosage to adalimumab 40 mg eow at Week 28 (after 52 or 28 weeks of total adalimumab exposure).

Participant Flow:   Overall Study

	Adalimumab 40 mg Every Other Week	Adalimumab 80 mg Every Other Week
STARTED	89	58
COMPLETED	67	45
NOT COMPLETED	22	13

Reporting Groups

	Description
Adalimumab 40 mg Every Other Week	Participants who had received adalimumab 40 mg eow during Study M04-688 (NCT00338754) or who had received placebo during Study M04-688 (NCT00338754) and were re-randomized to receive adalimumab 40 mg eow during this study.
Adalimumab 80 mg Every Other Week	Participants who had received adalimumab 80 mg eow during Study M04-688 (NCT00338754) or who had received placebo during Study M04-688 (NCT00338754) and were re-randomized to receive adalimumab 80 mg eow during this study. All participants had to reduce their dosage to adalimumab 40 mg eow at Week 28 (after 52 or 28 weeks of total adalimumab exposure).

Baseline Measures

	Adalimumab 40 mg Every Other Week	Adalimumab 80 mg Every Other Week	Total
Number of Participants   [units: participants]	89	58	147
Age   [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	80	56	136
>=65 years	9	2	11
Age   [units: years] Mean ± Standard Deviation	45.1  ± 13.39	42.9  ± 11.88	44.2  ± 12.82
Gender   [units: participants]
Female	13	10	23
Male	76	48	124
Region of Enrollment   [units: participants]
Japan	89	58	147

1.  Primary:

Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)   [ Time Frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab ]

2.  Secondary:

Number of Participants With a 75% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI75 Response)   [ Time Frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab ]

3.  Secondary:

Number of Participants With a 90% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI90 Response)   [ Time Frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab ]